BWX Technologies, Inc. (NYSE: BWXT) announced on August 3 that it has entered a definitive agreement to sell its medical business, comprising BWXT Medical and Kinectrics’ stable medical isotopes unit, to Nordic Capital, a European private equity firm with a healthcare focus, in a transaction valued at up to $800 million. For investors, the deal marks a strategic narrowing: BWXT is exiting the radiopharmaceutical supply business to concentrate capital and management attention on its core nuclear national security and commercial nuclear power operations, while keeping a minority stake and an ongoing supply role in the business it is selling.

Deal Structure and Terms

Under the agreement, BWXT will retain what the company calls a meaningful minority ownership stake in the divested business and will continue supplying specialized isotope and radiochemical expertise to it going forward, so this is a partial exit rather than a clean break. The release states the deal is valued at up to $800 million but does not break down how much of that figure is fixed consideration versus contingent on future milestones, a detail investors will want from the definitive transaction documents once they become available. The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026.

What’s Being Sold

BWXT Medical and Kinectrics’ isotopes business supply the raw and processed radioactive isotopes used in nuclear medicine, including materials for diagnostic imaging scans such as PET and SPECT, as well as for radiotherapeutic cancer treatments that deliver targeted radiation to tumors. This is a specialized, capital-intensive supply chain distinct from BWXT’s larger nuclear-reactor and defense-manufacturing businesses, and it is part of the rationale management gave for separating it out.

Why BWXT Is Selling

BWXT President and CEO Rex D. Geveden said the company has roughly tripled the medical business’s revenue and expanded its product portfolio, including novel therapeutic isotopes, since acquiring it in 2018. He framed the sale as a way to let the medical business grow under an owner focused on healthcare while BWXT redirects resources to its nuclear national security and nuclear power segments. Nordic Capital partner Christian Hedegaard said the firm sees significant potential to scale the business and expand access to radiopharmaceutical therapy, citing the firm’s experience spanning both pharmaceuticals and broader life sciences investing as a fit for a sector he described as sitting at the intersection of the two. These are characterizations from the companies themselves rather than independently verified projections.

Nordic Capital’s Bet on Radiopharma

Nordic Capital is a private, European-headquartered investment firm, not a publicly traded company, so no stock ticker applies to it. According to its own description in the release, it manages roughly 39 billion euros in assets, has operated for more than 35 years, and invests in middle-market companies across Northern Europe and North America, with dedicated advisory teams covering healthcare, technology and payments, financial services, and industrial technology. Its interest in BWXT’s medical business fits a broader pattern of private capital moving into specialized life-sciences supply chains, including nuclear medicine and radiopharmaceuticals. That interest has grown alongside the wider radiopharmaceutical field, where approved radioligand cancer therapies, such as Novartis’s targeted treatments for prostate cancer and neuroendocrine tumors, have shown investors that isotope-based products can support a durable commercial market beyond diagnostic imaging alone. The release itself does not provide market-size or growth figures for the sector, and none beyond this general industry context are estimated here.

Advisors and Risk Factors

Solomon Partners is serving as exclusive financial advisor to BWXT, with Stikeman Elliott as legal counsel; Kirkland & Ellis LLP and McCarthy Tétrault are serving as legal counsel to Nordic Capital. BWXT’s own forward-looking statement disclaimer in the release cautions that the anticipated benefits of the divestiture, and the timing of its close, are subject to risks including regulatory approval, satisfaction of other customary closing conditions, and potential business disruption tied to the transaction itself, and that actual results could differ materially from what the company currently anticipates.

Where This Leaves BWXT

The divestiture follows BWXT’s broader positioning as a nuclear-focused industrial supplier: the company describes itself as a Fortune 1000 manufacturer with more than 11,000 employees, 19 manufacturing facilities, and 14 strategic partnerships supporting U.S. and Canadian government customers across national security, clean energy, and environmental restoration work, in addition to nuclear medicine. Selling the medical unit while keeping a minority stake lets BWXT continue collecting a share of any future upside in radiopharmaceuticals without directing further capital or management bandwidth toward growing that business itself.

What’s Next

Assuming the deal closes as expected by the end of 2026, BWXT will retain a specialized isotope-supply role and a minority financial interest in the divested business, while its core operations going forward should reflect a narrower focus on nuclear security and power generation. Terms beyond what’s described above, including how the up-to-$800-million figure breaks down, have not been disclosed and would typically become clearer as the transaction moves toward closing. This article covers a proposed corporate transaction and is not an investment recommendation.

Sources

• BWXT Selling Medical Business to Nordic Capital in Transaction Valued at up to $800 Million, PRNewswire, August 3, 2026.

Editorial Disclosure

This article is based on a press release issued by BWX Technologies, Inc. and Nordic Capital on August 3, 2026, distributed via PRNewswire. BWX Technologies trades on the New York Stock Exchange under the ticker BWXT; Nordic Capital is a privately held investment firm and does not trade under a stock ticker. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the anticipated benefits, structure, or timing of the transaction are forward-looking and involve risks and uncertainties, including regulatory approval and other closing conditions; actual results may differ materially. This article is for informational and educational purposes only and does not constitute investment advice. See our full Disclaimer.